All In Biotech

NDA 214487 · Chemocentryx

Tavneos

Avacopan · Oral · Complement 5a Receptor Antagonist

NovelOrphan

CDER novel approval, Oct 7, 2021: To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids

Last checked: Nov 20, 2026Latest source record: Jun 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 7, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

4 Phase 3, 6 recruiting

FAERS reports

6,762

5,036 serious, 691 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2026.

TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. ( 1 )

Mechanism: Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration. The precise mechanism by which avacopan exerts a therapeutic effect in patients with ANCA-associated vasculitis has not been definitively established.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TAVNEOS · AVACOPAN 10MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avacopan" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hospitalisation1,026
  • death414
  • off label use373
  • therapy interrupted354
  • diarrhoea272
  • fatigue270
  • nausea249
  • pneumonia245
  • headache183
  • covid-19176
  • product dose omission issue158
  • dialysis145

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20218
2022462
20231,671
20241,242
20251,727
20261,652

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tavneos (Avacopan)

2024 spending

$76.0M

Beneficiaries

828

4,746 claims

Per beneficiary

$91,847

$89.18 per unit

View as table
YearSpending
2020$0
2021$195,550
2022$11,726,921
2023$33,951,025
2024$76,049,420

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Chemocentryx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.